Author(s): Soumya Khare, Tanushree Chatterjee, Shailendra Gupta, Ashish Patel

Email(s): soumyashrivastava82@gmail.com

DOI: 10.52711/0974-360X.2023.00678   

Address: Soumya Khare1*, Tanushree Chatterjee2, Shailendra Gupta3, Ashish Patel1
1Chhattisgarh Swami Vivekanand Technical University, Bhilai, India.
2Raipur Institute of Technology, Raipur, India.
3Department of Systems Biology and Bioinformatics, University of Rostock, Rostock Germany.
*Corresponding Author

Published In:   Volume - 16,      Issue - 9,     Year - 2023


ABSTRACT:
Beta thalassemia is a disorder of globin gene synthesis resulting in the absent production of beta globin chain in RBC. The property of inducing gamma globin gene expression by the search for bioactive compounds exhibiting is of great interest. Regulation of HDAC activity by dietary flavones couldhave important implication in developing epigenetic therapy to regulate the cell geneexpression. Several pharmacological agents have been identified overthe past two decades that reactivate gamma globin gene transcription through differentcellular system. We will search for the complementary and alternative medicine (CAM)which regulated switch from fetal to adult globin gene expression could be prevented hasresult in the development of new class of therapeutic agent consisting of some bioactivecompounds such as flavanone for the treatment of beta thalassemia. Flavones one suchmolecule of plant origin are known to interfere with HDAC2 enzyme and to enhance theacetylation restoring cell homeostasis, p38 MAPK pathway. Induction of HbF expression inerythroid cells is an important and another therapeutic approach in beta thalassemia. We used Schrodinger suites to develop computational approaches for estimating drug and target binding affinities. The target enzyme's sequence alignments contain 539 amino acid residues, and bioactive compounds that act as ligand molecules were acquired from the plant Andrographis paniculata. We used molecular docking, and ADME analysis. The current study explores the binding pattern of Andrographoilde and Vorinostat (SAHA) against their target protein (PDBIDs: 6G3O), respectively using molecular docking approaches. The molecular docking results show that Andrographoilde binds within the active region of HDAC2 inhibitors by forming hydrogen bonds against ASP104 and TYR 308 respectively. However, the Vorinostat interacts with TYR 308 and GLY 142respectively. Our comparative results show that andrographoilde may be a similar therapeutic agent for managing beta thalassemia as compare to vorinostat. However, functional studies are needed to confirm their proposed relevance in beta thalassemia in vitro and in vivo evaluation studies are required.


Cite this article:
Soumya Khare, Tanushree Chatterjee, Shailendra Gupta, Ashish Patel. Molecular Docking of Andrographoilde and HDAC2 inhibitor an approach to manage for Beta Thalassemia. Research Journal of Pharmacy and Technology 2023; 16(9):4143-7. doi: 10.52711/0974-360X.2023.00678

Cite(Electronic):
Soumya Khare, Tanushree Chatterjee, Shailendra Gupta, Ashish Patel. Molecular Docking of Andrographoilde and HDAC2 inhibitor an approach to manage for Beta Thalassemia. Research Journal of Pharmacy and Technology 2023; 16(9):4143-7. doi: 10.52711/0974-360X.2023.00678   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2023-16-9-22


REFERENCES:
1.    Noel. Hey, Chun. Hay. Natural remedies for the treatment of beta thalassemia and sickle cell anaemia – current status and perspectives in fetal haemoglobin reactivation, International Scholarly Research Notices. 2014:1-11.  doi: 10.1155/2014/123257
2.    A. Varma, H. Padh, N. Shrivastava. Andrographolide: a new plant-derived antineoplastic entity on horizon. Evid Based Complement Alternat Med. 2011:1-9.doi: 10.1093/ecam/nep135
3.    Ginder, G. D. Epigenetic regulation of fetal globin gene expression in adult erythroid cells. Translational Research.2015;165(1):115–125. DOI: 10.1016/j.trsl.2014.05.002
4.    A. Beshlawy, M. Hamdy, M. Ghamrawy. Fetal globin induction in beta thalassemia, Haemoglobin. 2009; 33(1): 197–203.DOI: 10.3109/03630260903351882
5.    N. Bianchi, C. Zuccato, I. Lampronti, M. Borgatti, R. Gambari. Fetal haemoglobin inducers from the natural world: a novel approach for identification of drugs for the treatment of β-thalassemia and Sickle-cell anaemia, Evidence-based Complementary and Alternative Medicine. 2009; 6(2):141–151. doi: 10.1093/ecam/nem139
6.    Hassana Fathalla, George F Atweh. Induction of fetal haemoglobin in the treatment of sickle cell anaemia. TheAmerican society of Haematology. 2006; 58: 57-62. DOI: 10.1182/asheducation-2006.1.58
7.    S. P. Perrine., S.A.Castaneda, M.S., Boosalis., G. L. White, B. M. Jones, and R. Bohacek. Induction of fetal globin in β-thalassemia: cellular obstacles and molecular progress, Annals of the New York Academy of Sciences. 2005; 1054: 257–265. DOI: 10.1111/j.1749-6632.2010.05593
8.    H. Cao, G. Stamatoyannopoulos, M. Jung. Induction of human γ globin gene expression by histone deacetylase inhibitors. Blood. 2004; 103(2):701–709. https://doi.org/10.1182/blood-2003-02-0478
9.    S. Pace, G. L. White, G. J. Dover, M. S. Boosalis, D. V. Faller, and S. P. Perrine. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo, Blood. 100; 13: 2002, 4640–4648.doi: 10.1182/blood-2002-02-0353
10.    A. Panja, A. Basu, Pharmacogenomics of the Drugs used for the Treatment of Thalassemia, J. Cytol. Histol. 2015; 6(5): 1-3.DOI: 10.4172/2157-7099.1000360
11.    Peart MJ, Smyth GK, van Laar RK, et al.  Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2005; 102: 3697-3702. DOI: 10.1073/pnas.0500369102
12.    Ruefli AA, Ausserlechner MJ, Bernhard D, et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci USA. 2001; 98:10833-10838. DOI: 10.1073/pnas.191208598
13.    PubChem https://pubchem.ncbi.nlm.nih.go(last accessed 2020/09/10).
14.    RCSB PDBhttp://www.rcsb.org. (last accessed 2020/09/29).
15.    LigPrep, version 3.8, Schrödinger, LLC, New York, 2020. (last accessed 2020/09/29).    
16.    E. Harder, W. Damm, J. Maple et al. OPLS3: a force field providing broad coverage of drug-like small molecules and proteins. Journal of Chemical Theory and Computation, vol. 12, no. 1, pp. 281–296, 2016.View at: Publisher Site | Google Scholar
17.    K.K. Kakarala, K. Jamil, V. Devaraji. Structure and putative signalingmechan- ism of protease activated receptor 2 (PAR2)– a promising target for breast cancer. J. Mol. Graph. Model. 2014; 53: 179–199. doi: 10.1016/j.jpha.2017.07.006
18.    Glide, version 8.6, Schrödinger, LLC, New York, 2020. (last accessed 2020/09/29).
19.    K.M. Elokely, R.J. Doerksen, Docking challenge: protein sampling and mole- cular docking performance, J. Chem. Inf. Model. 2013; 53: 1934–1945.Doi:10.1021/ci400040d
20.    T.A. Binkowski, W. Jiang, B. Roux, et al., Virtual high-throughput ligand screening, Methods Mol. Biol. 2014; 1140: 251–261. DOI: 10.1007/978-1-4939-0354-2_19
21.    X.Y. Meng, H.X. Zhang, M. Mezei, et al., Molecular docking: a powerful ap- proach for structure-based drug discovery, Curr. Comput. Aid. Drug Des. 2011; 7: 146–157.DOI: 10.2174/157340911795677602
22.    T. Katsila, G.A. Spyroulias, G.P. Patrinos, Computational approaches in target identification and drug discovery, Comput. Struct. Biotechnol. J. 2016; 14: 177–184.doi: 10.1016/j.csbj.2016.04.004
23.    Qik Prop, version 6.3, Schrödinger, LLC, New York, 2020.(last accessed 2020/10/03).
24.    F. Ntie-Kang, L.L. Lifongo, J.A. Mbah, et al., In silico drug metabolism and phar-macokinetic profiles of natural products from medicinal plants in the Congo basin, In Silico Pharmacol. 2013 doi: 10.1186/2193-9616-1-12
25.    Seto, E.; Yoshida, M. Erasers of Histone Acetylation: The Histone Deacetylase Enzymes. Cold. Spring Harb. Perspect. Biol. 2014:6-11.
26.    Calabrese, S. H. Berman, J. G. Babish.  A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytotheraphy Research. 2000; 14(5): 333–338. DOI: 10.1002/1099-1573(200008)14:
27.    P. K. Singha, S. Roy, S. Dey. Antimicrobial activity of Andrographis paniculata. Fitoterapia. 2003; 74(7): 692– 694. DOI: 10.1016/s0367-326x(03)00159-x

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available